San Francisco, United States
PYC Therapeutics, founded in 2005, is a clinical-stage biotech company focused on transforming patient lives through a new generation of RNA therapeutics. Positioned within the Biotechnology industry, PYC Therapeutics addresses the root causes of genetic diseases by leveraging scientific rigor, clinical insights, and a proprietary drug delivery system.
They stand out with their innovative approach using RNA therapies that modulate protein production in patients where such proteins are low or absent. Their breakthrough comes from using cell-penetrating peptides (CPPs) to enhance intracellular RNA potency, opening new pathways for treating genetic diseases with limited existing therapies.
The company’s last major financial milestone involved a $537.00M Post IPO Equity investment dated 01 February 2026. As they continue to advance their clinical-stage therapies, PYC Therapeutics presents a compelling proposition for investors seeking ground-breaking solutions in the biotech sector.
